시장보고서

상품코드

1424141

세계 인간용 백신 보조제 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 - 유형별, 용도별, 최종 사용자별, 지역별

Human Vaccine Adjuvants Market Size and Forecast, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), End User, and Geography

발행일: 2024년 01월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 199 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인간용 백신 보조제 시장은 2022년 15억 7,100만 달러로 평가되었꼬 2030년에는 44억 8,900만 달러에 이를 것으로 예측됩니다. 예측기간 동안 복합 연간 성장률(CAGR) 14.0%로 성장할 것으로 추정됩니다. 인간 백신 보조제 시장의 성장을 가속하는 주요 요인으로는 만성 질환의 유병률 증가, 예방 접종 프로그램에 대한 관심 증가 등이 있습니다.

인간용 백신 보조제 시장 시장 기회

보조제는 백신의 효능과 안전성을 향상시키기 때문에 제약 산업의 확대가 보조제 수요에 긍정적 영향을 미칠 것으로 예상됩니다. 제약업계에서는 감염, 암, 자가면역질환에 대한 관심이 높아지고 있으며, 이러한 특정 질환영역을 표적으로 한 개별화 백신과 애주번트를 개발하기 위한 기반이 제공되고 있습니다. 이것은 보조제 제조자에게 이러한 질병의 백신에 대한 면역 반응을 향상시키는 특수 보조제를 개발할 수있는 기회입니다.

미국은 세계에서 가장 연구개발 집약형 제약산업 중 하나입니다. 유럽 제약 단체 연합회(EFPIA)에 따르면 북미 시장(미국과 캐나다)의 점유율은 49.1%로 유럽, 중국, 일본을 크게 이어 세계 최대 시장을 유지하고 있습니다. 미국은 혁신적인 R&D 투자의 세계 리더로 지난 10년간 세계 신분자의 절반 이상을 생산했습니다. 또한 EFPIA에 따르면 2021년에는 세계 의약품 매출의 49.1%를 북미가 차지하는 반면 유럽은 23.4%입니다.

마찬가지로 EFPIA에 따르면 2016년부터 2021년 사이에 브라질, 중국, 인도 제약업계는 각각 11.7%, 6.7%, 11.8% 성장했으며, 상위 5개 EU 시장과 미국 시장은 각각 평균 5.8%, 5.6% 시장 성장을 기록했습니다. 게다가, 인도 브랜드 에퀴티 재단(IBEF)에 따르면, 인도는 세계 제약 업계의 주요 신흥국입니다. 이 나라는 세계 최대의 제네릭 의약품 무역국이며 전 세계 공급량의 거의 20%를 차지합니다. 또한 세계 예방접종 수요의 50%를 공급하고 있습니다. 국내 제약 업계에는 3,000개의 제약 회사와 -10,500의 제조 단위 네트워크가 있습니다. 인도 정부의 공식 발표에 따르면 인도 제약 부문 시장 규모는 약 500억 달러이며, 그 중 250억 달러 이상이 수출 때문입니다. 인도는 세계 제네릭 의약품 수출의 약 20%를 차지합니다. 또한 일본은 세계 최대의 의약품 시장 중 하나입니다. 후생노동성의 '의약품 생산동태통계'에 따르면 2020년 일본의 의료용·비의료용 의약품 시장은 1,070억 달러였습니다.

업계가 진화와 혁신을 계속하고 있는 가운데, 개별화 백신의 개발을 서포트할 수 있는 애주번트에 대한 수요가 높아지고 있어, 인간용 백신 보조제 시장의 대폭적인 성장과 투자의 원동력이 되고 있습니다. 따라서 세계 제약 산업의 성장은 앞으로 몇 년동안 인간 백신 보조제 시장에 유리한 성장 기회를 가져올 가능성이 높습니다.

인간용 백신 보조제 시장을 저해하는 요인

인간용 백신 보조제의 제조는 엄격한 규제 요건과 품질 관리 대책을 수반하는 복잡한 공정입니다. 보조제 제조에는 최종 제품의 순도, 안전성 및 효능을 보장하기 위해 적절한 제조 기준(GMP) 및 기타 규제 기준을 엄격하게 준수하는 특수 장비 및 시설이 필요합니다. 이러한 요건을 충족시키기 위한 자원과 전문지식이 한정되어 있기 때문에 제조업체, 특히 중소기업이나 신규 참가기업에 있어서는 큰 과제가 될 수 있습니다.

규제 문제는 또한 인간 백신 보조제 시장의 억제에 큰 역할을 합니다. 보조제는 백신의 중요한 성분으로 여겨지고 있으며, 유럽의 유럽 의약청(EMA)과 미국 식품의약국(FDA)과 같은 보건 당국의 엄격한 규제 감독을 받고 있습니다. 보조제의 규제 당국에 의한 승인 프로세스는 안전성, 효능 및 품질을 입증하기 위해 광범위한 전임상 및 임상 데이터가 필요하기 때문에 길고 복잡합니다. 규제 당국의 승인을 얻는데 필요한 비용과 시간은 상당한 것이 되기 때문에 제조업체에게는 큰 장벽이 될 수 있습니다. 따라서 위의 요인은 인간 백신 보조제 시장의 성장을 방해합니다.

인간용 백신 보조제 시장 부문별 개요

인간용 백신 보조제 시장은 유형별로 미립자 보조제, 에멀젼 보조제, 배합 보조제 등으로 구분됩니다. 미립자 보조제 부문은 2022년 시장에서 큰 점유율을 차지합니다. 그러나 에멀젼 보조제 부문은 2022-2030년간 시장에서 더 높은 복합 연간 성장률(CAGR)을 기록할 것으로 예상됩니다. 미립자 보조제는 종종 나노미터 또는 마이크로미터 크기의 입자로 구성되며 병원체와 세포 구조를 모방하여 견고한 면역 반응을 자극하도록 설계되었습니다. 이러한 보조제는 면역 세포에 의한 항원의 흡수를 촉진하고 면역 활성화를 촉진합니다. 미립자 애주번트의 현저한 예로는 알루미늄염(명반)을 들 수 있고, 이들은 항체 반응을 증강시키기 위해 인간용 백신에 수십 년에 걸쳐 사용되어 왔고, 바이러스 유사 입자(VLP)나 나노 입자 기반 보조제와 같은 새로운 개발도 진행되고 있습니다.

인간용 백신 보조제 시장은 용도별로 인플루엔자, 간염, 인유두종 바이러스(HPV) 등으로 구분됩니다. 인플루엔자 분야는 2022년 시장에서 가장 큰 점유율을 차지하며(2022년-2030년)간 시장에서 가장 높은 복합 연간 성장률(CAGR)을 기록할 것으로 예상됩니다. 독감 백신은 계절성 독감의 유행과 유행의 가능성을 예방하는 데 매우 중요합니다. 인플루엔자 백신은 빠르게 진화하는 바이러스를 대상으로 하므로 유행 균주에 맞게 지속적으로 백신을 업데이트해야 합니다. 인플루엔자 백신에 사용되는 애주번트는 특히 노인 및 면역결핍자와 같은 고위험 집단에서 면역반응을 증진시킵니다. 보조제는 또한 광범위하게 방어적인 교차 반응성 면역 반응의 발현을 지원합니다.

최종 사용자별로, 인간용 백신 보조제 시장은 제약·바이오테크놀러지 기업, CMO·CRO, 기타로 구분됩니다. 제약 및 생명공학 기업 부문은 2022년 시장에서 가장 큰 점유율을 차지하며 2022-2030년간 시장에서 가장 높은 복합 연간 성장률(CAGR)을 기록할 것으로 예상됩니다. 제약·바이오테크놀러지 기업은 다양한 감염증과 건강상태를 타겟으로 하는 애주번트 백신 제제를 포함한 백신의 연구, 개발, 상업화에 있어 중심적인 역할을 하고 있습니다. 이들 기업은 백신 혁신의 최전선에 서서 전임상 및 임상 개발 단계를 통해 보조제 기술, 백신 후보, 보조제 첨가 백신 제제의 발견과 최적화를 추진하고 있습니다.

인간용 백신 보조제 시장 지역별 개요

2022년 인간용 백신 보조제 시장 점유율은 북미가 최대였습니다. 북미의 인간용 백신 보조제 시장에서는 미국이 큰 점유율을 차지하고 있습니다. 이 나라 시장 성장은 주로 건강 관리에 대한 정부 지출 증가와 감염을 보다 효율적으로 치료하기 위한 신규 백신 제형에 대한 수요의 급증으로 인한 것입니다. 미국 메디케어 및 메디케이드 서비스 센터에 따르면 미국의 국민 의료비는 2021년 2.7% 증가하여 4조 3,000억 달러, 1인당 12,914달러에 달했습니다. 의료비는 국내총생산(GDP)의 18.3%를 차지합니다. 미국 보건사회복지성의 발표에 따르면 2019년부터 2028년까지 국민의료비는 연률 5.4%로 성장했으며 2028년에는 6조 2,000억 달러에 달할 것으로 예상됩니다. 의료 지출 증가는 백신의 연구 개발에 대한 자금 배분 증가로 이어져 인간용 백신 보조제 수요를 부추길 수 있습니다.

2020년 7월에 발표된 Global Burden of Disease 연구에서 얻은 새로운 지식에 따르면 미국에서는 비전염성 질환과 감염증의 부담이 크게 증가하고 있습니다. 존스 홉킨스 대학에 따르면 SARS, 라임병, 뎅기열, 웨스트나일 바이러스, 지카바이러스 감염 등의 사례가 미국에서는 지난 20년간 급증하고 있습니다. 또한 말라리아, 결핵, 콜레라, 백일해, 인플루엔자, 폐렴구균 감염, 임질 등 재흥 질환의 발생률도 증가하고 있습니다. 마찬가지로 미국 질병대책예방센터(CDC)에 따르면 인플루엔자는 2010년부터 2022년 사이에 연간 10만명에서 71만명의 입원과 4900명에서 5만2000명의 사망을 가져왔습니다. 2023년 HPV와 암에 관한 ICO/IARC 정보센터의 보고에 의하면, 미국에는 HPV와 관련된 자궁경부암을 발병할 위험이 있는 15세 이상의 여성이 1억 4,050만명 있습니다. 미국에서는 일반 인구 여성의 3.9% 가까이가 어느 시점에서 자궁경부 HPV16/18 감염을 보유하고 있는 것으로 예측되고 침윤성 자궁경부암의 71.2%가 HPV16 또는 18에 기인하고 있습니다. 이와 같이 다양한 감염과 재흥 질환의 발생률 증가는 기업의 백신 개발에 대한 노력을 뒷받침하고 미국에서의 인간용 백신 보조제 시장의 성장에 박차를 가하고 있습니다.

미국 정부는 국내에서 의약품 및 헬스케어 제품을 개발·상업화하기 위한 환경 정비에 노력하고 있습니다. 미국에는 화이자, 노바티스, 보스턴·사이언티픽, 인테그라·라이프 사이언시스, 암젠, 애봇 등 의약품·의료기기 시장의 잠재적 기업이 복수 존재해, 의약품·의료기기 업계의 혁신에 관한 다양한 특허를 받고 있습니다. 이와 같이, 다양한 제약 대기업에 의한 의약품 개발 활동 증가는 미국의 인간용 백신 보조제 시장을 강화하고 있습니다.

인간용 백신 보조제 시장에 관한 보고서를 작성할 때 참조한 주요 1차 정보 및 2차 정보에는 세계은행 데이터, 국민보건서비스(NHS), FDA(식품의약품국), EMA(유럽의약품청), WHO(세계 보건기구) 등이 있습니다.

인간용 백신 보조제 시장 : 주요 시장 역학
시장 성장 촉진요인
- 만성 질환 증가
- 예방접종 프로그램에 대한 주목의 고조
시장 성장 억제요인
- 제조의 복잡성과 규제상의 과제
시장 기회
- 제약 업계의 성장
향후의 동향
- 개별화 백신의 동향 증가
성장 촉진요인과 억제요인의 영향

제6장 인간용 백신 보조제 시장 : 시장 분석

인간용 백신 보조제 시장 수익(2022년-2030년)
인간용 백신 보조제 시장 예측 분석

제7장 인간용 백신 보조제 시장 분석 : 유형별

미립자 보조제
에멀젼 애주번트
배합 애주번트
기타

제8장 인간용 백신 보조제 시장 분석 : 용도별

인플루엔자
간염
인유두종 바이러스(HPV)
기타

제9장 인간용 백신 보조제 시장 분석 : 최종 사용자별

제약 기업 및 생명 공학 기업
CMO 및 CRO
기타

제10장 인간용 백신 보조제 시장 :지역별 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- APAC 기타 국가
중동 및 아프리카
- 사우디아라비아
- 남아프리카
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 업계 정세

제12장 기업 프로파일

Novartis AG
Dynavax Technologies Corp
CSL Ltd
Seppic SA
SPI Pharma Inc
Hawaii Biotech Inc
Croda International Plc
Novavax Inc
Phibro Animal Health Corp
Creative Biolabs Inc

제13장 기업 프로파일 부록

BJH 24.02.20

The global human vaccine adjuvants market is expected to reach US$ 4.489 billion in 2030 from US$ 1.571 billion in 2022. The market is estimated to grow with a CAGR of 14.0% from 2022 to 2030. Key factors driving the human vaccine adjuvants market growth include the rising prevalence of chronic diseases and growing focus on immunization programs.

Market Opportunities of Human Vaccine Adjuvants Market

The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry's increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases.

The US has one of the most R&D-intensive pharmaceutical industries globally. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the North America market (US and Canada) remained the world's largest market with a 49.1% share, well ahead of Europe, China, and Japan. The US is the global leader in innovative R&D investments, and the country produced over half of the world's new molecules in the last decade. Additionally, as per EFPIA, in 2021, North America accounted for 49.1% of global pharmaceutical sales, compared with 23.4% for Europe.

Similarly, according to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion.

As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the human vaccine adjuvants market in the coming years.

Factors Hampering Human Vaccine Adjuvants Market

Manufacturing human vaccine adjuvant is a complex process involving stringent regulatory requirements and quality control measures. The production of adjuvants requires specialized equipment and facilities with strict adherence to Good Manufacturing Practices (GMP) and other regulatory standards to ensure the final product's purity, safety, and efficacy. This can pose significant challenges for manufacturers, especially smaller companies or new entrants, owing to limited resources and expertise to meet these requirements.

Regulatory challenges also play a significant role in restraining the human vaccine adjuvants market. Adjuvants are considered critical components of vaccines, and they are subjected to strict regulatory oversight by health authorities such as the European Medicines Agency (EMA) in Europe and the Food and Drug Administration (FDA) in the US. The regulatory approval process for adjuvants can be lengthy and complex, requiring extensive preclinical and clinical data to demonstrate safety, efficacy, and quality. It can pose a significant barrier for manufacturers, as the cost and time required to obtain regulatory approval can be substantial. Thus, the factors mentioned above hamper the growth of the human vaccine adjuvants market.

Human Vaccine Adjuvants Market: Segmental Overview

Based on type, the human vaccine adjuvants market is segmented into particulate adjuvants, emulsion adjuvants, combination adjuvants, and others. The particulate adjuvant segment held a larger share of the market in 2022. However, the emulsion adjuvants segment is expected to register a higher CAGR in the market from 2022 to 2030. Particulate adjuvants consist of particles, often of nanometer or micrometer size, designed to mimic pathogens or cellular structures, stimulating a robust immune response. These adjuvants enhance antigen uptake by immune cells and promote immune activation. Notable examples of particulate adjuvants include aluminum salts (Alum), which have been used for decades in human vaccines to enhance antibody responses, and newer developments such as virus-like particles (VLPs) and nanoparticle-based adjuvants.

By application, the human vaccine adjuvants market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Influenza vaccines are crucial for preventing seasonal flu outbreaks and potential pandemics. They target a rapidly evolving virus, requiring continual vaccine updating to match circulating strains. Adjuvants used in influenza vaccines enhance immune responses, particularly in high-risk populations such as the elderly or immunocompromised individuals. They also support the development of broadly protective, cross-reactive immune responses.

In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Pharmaceutical and biotechnology companies play a central role in the research, development, and commercialization of vaccines, including adjuvanted vaccine formulations, targeting diverse infectious diseases and health conditions. These companies are at the forefront of vaccine innovation, driving the discovery and optimization of adjuvant technologies, vaccine candidates, and adjuvanted vaccine formulations through preclinical and clinical development stages.

Human Vaccine Adjuvants Market: Geographical Overview

North America accounted for the largest global human vaccine adjuvants market share in 2022. The US holds a significant share of North America's human vaccine adjuvants market. The market growth in this country is mainly ascribed to rising government spending on healthcare and a surging demand for novel vaccine formulations to treat infectious diseases more efficiently. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019-2028, reaching US$ 6.2 trillion by 2028. The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants.

According to new findings derived from the Global Burden of Disease study published in July 2020, there is a large and increasing burden of noncommunicable and infectious diseases in the US. According to Johns Hopkins University, the cases of diseases such as SARS, Lyme disease, dengue fever, West Nile virus, and Zika virus infection have increased rapidly in the last two decades in the US. Also, the same source affirmed an increase in the incidence of re-emerging diseases such as malaria, tuberculosis, cholera, pertussis, influenza, pneumococcal disease, and gonorrhea. Similarly, according to the Centers for Disease Control and Prevention (CDC), flu has resulted in 100,000 to 710,000 hospitalizations and 4,900 to 52,000 deaths annually between 2010 and 2022. According to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, the US has a population of 140.5 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Nearly 3.9% of women in the US in the general population are projected to harbor cervical HPV16/18 infection at a given time, and 71.2% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, a rise in the incidences of various infections and re-emerging diseases boosts companies' efforts in vaccine development, fueling the human vaccine adjuvants market growth in the US.

The US government strives to create a conducive environment for developing and commercializing pharmaceutical and healthcare products in the country. The country has several potential pharmaceutical and medical device market players, including Pfizer, Novartis, Boston Scientific, Integra LifeSciences, Amgen, and Abbott, with various patents for their pharmaceutical and medical device industry innovations. Thus, an increase in drug development activities by various pharmaceutical giants bolsters the human vaccine adjuvants market in the US.

A few of the major primary and secondary sources referred to while preparing the report on the human vaccine adjuvants market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the human vaccine adjuvants market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the human vaccine adjuvants market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Human Vaccine Adjuvants Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Human Vaccine Adjuvants Market - Key Market Dynamics

5.1 Human Vaccine Adjuvants Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Prevalence of Chronic Diseases
- 5.2.2 Growing Focus on Immunization Programs
5.3 Market Restraints
- 5.3.1 Manufacturing Complexities and Regulatory Challenges
5.4 Market Opportunities
- 5.4.1 Growing Pharmaceutical Industry
5.5 Future Trends
- 5.5.1 Rising Trend of Personalized Vaccines
5.6 Impact of Drivers and Restraints:

6. Human Vaccine Adjuvants Market - Global Market Analysis

6.1 Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
6.2 Human Vaccine Adjuvants Market Forecast Analysis

7. Human Vaccine Adjuvants Market Analysis - by Type

7.1 Particulate Adjuvant
- 7.1.1 Overview
- 7.1.2 Particulate Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Emulsion Adjuvant
- 7.2.1 Overview
- 7.2.2 Emulsion Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Combination Adjuvant
- 7.3.1 Overview
- 7.3.2 Combination Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Human Vaccine Adjuvants Market Analysis - by Application

8.1 Influenza
- 8.1.1 Overview
- 8.1.2 Influenza: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 Hepatitis
- 8.2.1 Overview
- 8.2.2 Hepatitis: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Human papilloma virus (HPV)
- 8.3.1 Overview
- 8.3.2 Human papilloma virus (HPV): Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Human Vaccine Adjuvants Market Analysis - by End User

9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.2 CMOs and CROs
- 9.2.1 Overview
- 9.2.2 CMOs and CROs: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

10. Human Vaccine Adjuvants Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America Human Vaccine Adjuvants Market Overview
- 10.2.2 North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
- 10.2.3 North America: Human Vaccine Adjuvants Market Breakdown, by Type
  - 10.2.3.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
- 10.2.4 North America: Human Vaccine Adjuvants Market Breakdown, by Application
  - 10.2.4.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
- 10.2.5 North America: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.2.5.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
- 10.2.6 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.2 United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.2.6.2.1 United States: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.2.6.2.2 United States: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.2.6.2.3 United States: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.2.6.3 Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.2.6.3.1 Canada: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.2.6.3.2 Canada: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.2.6.3.3 Canada: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.2.6.4 Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.2.6.4.1 Mexico: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.2.6.4.2 Mexico: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.2.6.4.3 Mexico: Human Vaccine Adjuvants Market Breakdown, by End User
10.3 Europe
- 10.3.1 Europe Human Vaccine Adjuvants Market Overview
- 10.3.2 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
- 10.3.3 Europe: Human Vaccine Adjuvants Market Breakdown, by Type
  - 10.3.3.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
- 10.3.4 Europe: Human Vaccine Adjuvants Market Breakdown, by Application
  - 10.3.4.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
- 10.3.5 Europe: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.3.5.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
- 10.3.6 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.2 Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.3.6.2.1 Germany: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.3.6.2.2 Germany: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.3.6.2.3 Germany: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.3.6.3 United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.3.6.3.1 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.3.6.3.2 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.3.6.3.3 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.3.6.4 France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.3.6.4.1 France: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.3.6.4.2 France: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.3.6.4.3 France: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.3.6.5 Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.3.6.5.1 Italy: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.3.6.5.2 Italy: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.3.6.5.3 Italy: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.3.6.6 Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.3.6.6.1 Spain: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.3.6.6.2 Spain: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.3.6.6.3 Spain: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.3.6.7 Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.3.6.7.1 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.3.6.7.2 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.3.6.7.3 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by End User
10.4 Asia Pacific
- 10.4.1 Asia Pacific Human Vaccine Adjuvants Market Overview
- 10.4.2 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
- 10.4.3 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type
  - 10.4.3.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
- 10.4.4 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application
  - 10.4.4.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
- 10.4.5 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.4.5.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
- 10.4.6 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.2 China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.4.6.2.1 China: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.4.6.2.2 China: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.4.6.2.3 China: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.4.6.3 Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.4.6.3.1 Japan: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.4.6.3.2 Japan: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.4.6.3.3 Japan: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.4.6.4 India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.4.6.4.1 India: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.4.6.4.2 India: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.4.6.4.3 India: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.4.6.5 Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.4.6.5.1 Australia: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.4.6.5.2 Australia: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.4.6.5.3 Australia: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.4.6.6 South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.4.6.6.1 South Korea: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.4.6.6.2 South Korea: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.4.6.6.3 South Korea: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.4.6.7 Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.4.6.7.1 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.4.6.7.2 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.4.6.7.3 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by End User
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Human Vaccine Adjuvants Market Overview
- 10.5.2 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
- 10.5.3 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
  - 10.5.3.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
- 10.5.4 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
  - 10.5.4.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
- 10.5.5 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.5.5.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
- 10.5.6 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.2 Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.5.6.2.1 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.5.6.2.2 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.5.6.2.3 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.5.6.3 South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.5.6.3.1 South Africa: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.5.6.3.2 South Africa: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.5.6.3.3 South Africa: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.5.6.4 United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.5.6.4.1 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.5.6.4.2 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.5.6.4.3 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.5.6.5 Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.5.6.5.1 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.5.6.5.2 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.5.6.5.3 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
10.6 South and Central America
- 10.6.1 South and Central America Human Vaccine Adjuvants Market Overview
- 10.6.2 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 | (US$ Million)
- 10.6.3 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
  - 10.6.3.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
- 10.6.4 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
  - 10.6.4.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
- 10.6.5 South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.6.5.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
- 10.6.6 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.2 Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.6.6.2.1 Brazil: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.6.6.2.2 Brazil: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.6.6.2.3 Brazil: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.6.6.3 Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.6.6.3.1 Argentina: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.6.6.3.2 Argentina: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.6.6.3.3 Argentina: Human Vaccine Adjuvants Market Breakdown, by End User
  - 10.6.6.4 Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.6.6.4.1 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
    - 10.6.6.4.2 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
    - 10.6.6.4.3 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User

11. Industry Landscape

11.1 Overview

12. Company Profiles

12.1 Novartis AG
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Dynavax Technologies Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 CSL Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Seppic SA
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 SPI Pharma Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Hawaii Biotech Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Croda International Plc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Novavax Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Phibro Animal Health Corp
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Creative Biolabs Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms